The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Hypoalbuminemia: a new risk factor for progression in patients with MGUS
Although monoclonal gammopathy of undetermined significance (MGUS) generally has a low risk of progression to symptomatic diseases like multiple myeloma (MM), identifying prognostic factors is crucial for patient stratification. In this interview, Elena Alejo, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses her recent retrospective study, which found that hypoalbuminemia, defined as serum albumin levels of 3.5 g/dL or less, was present in 8% of patients with MGUS. This group of patients demonstrated a shorter time to progression than those with normal serum albumin levels, suggesting that low albumin could serve as a prognostic factor for MGUS progression if validated in future studies. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
